Amneal Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US03168L1052

Introduction

This page provides a comprehensive analysis of the known insider trading history of Joseph Todisco. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Joseph Todisco has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:CRMD / CorMedix Inc. Chief Executive Officer, Director 530,721
US:AMRX / Amneal Pharmaceuticals, Inc. Executive Vice President 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Joseph Todisco. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases AMRX / Amneal Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in AMRX / Amneal Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2020-02-28 AMRX Todisco Joseph 40,000 3.6200 40,000 3.6200 144,800 346 5.91 91,600 63.26
2019-05-13 AMRX Todisco Joseph 15,000 9.8800 15,000 9.8800 148,200

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AMRX / Amneal Pharmaceuticals, Inc. Insider Trades
Insider Sales AMRX / Amneal Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AMRX / Amneal Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2021-12-02 AMRX Todisco Joseph 1,500 4.1000 1,500 4.1000 6,150 316 1.9600 -3,210 -52.20
2021-03-15 AMRX Todisco Joseph 36,330 6.8226 36,330 6.8226 247,865

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AMRX / Amneal Pharmaceuticals, Inc. Insider Trades
Insider Purchases CRMD / CorMedix Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in AMRX / Amneal Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2024-03-13 CRMD Todisco Joseph 13,561 3.7400 13,561 3.7400 50,718 229 13.5900 133,576 263.37
2023-09-08 CRMD Todisco Joseph 10,000 3.7100 10,000 3.7100 37,100
2023-05-17 CRMD Todisco Joseph 5,000 4.5800 5,000 4.5800 22,900
2022-11-15 CRMD Todisco Joseph 20,000 3.8200 20,000 3.8200 76,400
2022-08-24 CRMD Todisco Joseph 4,700 3.9200 4,700 3.9200 18,424
2022-05-16 CRMD Todisco Joseph 10,000 3.3800 10,000 3.3800 33,800

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CRMD / CorMedix Inc. Insider Trades
Insider Sales CRMD / CorMedix Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AMRX / Amneal Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CRMD / CorMedix Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Joseph Todisco as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-04-02 2025-04-01 4 CRMD CorMedix Inc.
Common Stock
M - Exercise 59,170 530,721 12.55 3.38 199,995 1,793,837
2025-01-22 2025-01-17 4 CRMD CorMedix Inc.
Common Stock
F - Taxes -23,977 471,551 -4.84 12.17 -291,800 5,738,776
2025-01-22 2025-01-17 4 CRMD CorMedix Inc.
Common Stock
A - Award 187,500 495,528 60.87
2025-01-14 2025-01-10 4 CRMD CorMedix Inc.
Common Stock
F - Taxes -17,829 308,028 -5.47 11.19 -199,507 3,446,833
2024-05-13 2024-05-10 4 CRMD CorMedix Inc.
Common Stock
F - Taxes -26,982 325,857 -7.65 5.17 -139,497 1,684,681
2024-03-14 2024-03-13 4 CRMD CorMedix Inc.
Common Stock
P - Purchase 13,561 352,839 4.00 3.74 50,718 1,319,618
2024-01-17 2024-01-12 4 CRMD CorMedix Inc.
Common Stock
F - Taxes -13,781 339,278 -3.90 3.47 -47,820 1,177,295
2024-01-17 2024-01-12 4 CRMD CorMedix Inc.
Common Stock
A - Award 133,333 353,059 60.68
2023-09-08 2023-09-08 4 CRMD CorMedix Inc.
Common Stock
P - Purchase 10,000 219,726 4.77 3.71 37,100 815,183
2023-05-18 2023-05-17 4/A CRMD CorMedix Inc.
Common Stock
P - Purchase 5,000 209,726 2.44 4.58 22,900 960,545
2023-05-17 2023-05-17 4 CRMD CorMedix Inc.
Common Stock
A - Award 5,000 209,726 2.44 4.58 22,900 960,545
2023-05-12 2023-05-10 4 CRMD CorMedix Inc.
Common Stock
F - Taxes -37,443 204,726 -15.46 5.30 -198,448 1,085,048
2022-11-16 2022-11-15 4 CRMD CorMedix Inc.
Common Stock
P - Purchase 20,000 242,169 9.00 3.82 76,400 925,086
2022-08-25 2022-08-24 4 CRMD CorMedix Inc.
Common Stock
P - Purchase 4,700 222,169 2.16 3.92 18,424 870,902
2022-05-17 2022-05-16 4 CRMD CorMedix Inc.
Common Stock
P - Purchase 10,000 217,469 4.82 3.38 33,800 735,045
2022-05-12 2022-05-10 4 CRMD CorMedix Inc.
Stock Option (Right to Buy Common Stock)
A - Award 500,000 500,000
2022-05-12 2022-05-10 4 CRMD CorMedix Inc.
Common Stock
A - Award 207,469 207,469
2022-05-10 2022-05-07 4 AMRX Amneal Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -4,442 0 -100.00
2022-05-10 2022-05-07 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
F - Taxes -1,562 327,194 -0.48 3.40 -5,311 1,112,460
2022-05-10 2022-05-07 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
M - Exercise 4,442 328,756 1.37
2022-03-03 2022-03-03 4 AMRX Amneal Pharmaceuticals, Inc.
Performance-Based Restricted Stock Units
A - Award 289,856 289,856
2022-03-03 2022-03-03 4 AMRX Amneal Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 144,928 144,928
2022-03-03 2022-03-01 4 AMRX Amneal Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -26,544 79,634 -25.00
2022-03-03 2022-03-01 4 AMRX Amneal Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -11,111 11,111 -50.00
2022-03-03 2022-03-01 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
F - Taxes -9,331 324,314 -2.80 4.45 -41,523 1,443,197
2022-03-03 2022-03-01 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
M - Exercise 26,544 333,645 8.64
2022-03-03 2022-03-01 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
F - Taxes -3,906 307,101 -1.26 4.45 -17,382 1,366,599
2022-03-03 2022-03-01 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
M - Exercise 11,111 311,007 3.70
2022-03-01 2022-02-27 4 AMRX Amneal Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -29,684 59,367 -33.33
2022-03-01 2022-02-27 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
F - Taxes -11,107 299,896 -3.57 4.59 -50,981 1,376,523
2022-03-01 2022-02-27 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
M - Exercise 29,684 311,003 10.55
2021-12-03 2021-12-02 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
S - Sale -1,500 281,319 -0.53 4.10 -6,150 1,153,408
2021-05-11 2021-05-07 4 AMRX Amneal Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -4,441 4,442 -49.99
2021-05-11 2021-05-07 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
F - Taxes -1,562 282,819 -0.55 5.20 -8,122 1,470,659
2021-05-11 2021-05-07 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
M - Exercise 4,441 284,381 1.59
2021-03-17 2021-03-15 4 AMRX Amneal Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise -36,330 36,331 -50.00
2021-03-17 2021-03-15 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
S - Sale -36,330 279,940 -11.49 6.82 -247,865 1,909,919
2021-03-17 2021-03-15 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
M - Exercise 36,330 316,270 12.98 2.75 99,908 869,742
2021-03-03 2021-03-01 4 AMRX Amneal Pharmaceuticals, Inc.
Performance-Based Restricted Stock Units
A - Award 212,356 212,356
2021-03-03 2021-03-01 4 AMRX Amneal Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 106,178 106,178
2021-03-02 2021-03-01 4 AMRX Amneal Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -11,111 22,222 -33.33
2021-03-02 2021-03-01 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
F - Taxes -3,906 279,940 -1.38 5.18 -20,233 1,450,089
2021-03-02 2021-03-01 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
M - Exercise 11,111 283,846 4.07
2021-03-02 2021-02-27 4 AMRX Amneal Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -29,683 89,051 -25.00
2021-03-02 2021-02-27 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
F - Taxes -10,972 272,735 -3.87 5.39 -59,139 1,470,042
2021-03-02 2021-02-27 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
M - Exercise 29,683 283,707 11.69
2020-05-08 2020-05-07 4 AMRX Amneal Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -4,442 8,883 -33.34
2020-05-08 2020-05-07 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
F - Taxes -2,212 254,024 -0.86 3.55 -7,853 901,785
2020-05-08 2020-05-07 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
M - Exercise 4,442 256,236 1.76
2020-03-03 2020-03-01 4 AMRX Amneal Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -11,111 33,333 -25.00
2020-03-03 2020-03-01 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
F - Taxes -6,162 251,794 -2.39 3.85 -23,724 969,407
2020-03-03 2020-03-01 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
M - Exercise 11,111 257,956 4.50
2020-03-03 2020-02-28 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
P - Purchase 40,000 246,845 19.34 3.62 144,800 893,579
2020-03-02 2020-02-27 4 AMRX Amneal Pharmaceuticals, Inc.
Performance-Based Restricted Stock Units
A - Award 237,468 237,468
2020-03-02 2020-02-27 4 AMRX Amneal Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 118,734 118,734
2019-11-14 2019-11-13 4 AMRX Amneal Pharmaceuticals, Inc.
Stock Option
A - Award 90,498 90,498
2019-11-14 2019-11-13 4 AMRX Amneal Pharmaceuticals, Inc.
Stock Option
D - Sale to Issuer -90,498 0 -100.00
2019-11-14 2019-11-13 4 AMRX Amneal Pharmaceuticals, Inc.
Stock Option
A - Award 72,661 72,661
2019-11-14 2019-11-13 4 AMRX Amneal Pharmaceuticals, Inc.
Stock Option
D - Sale to Issuer -72,661 0 -100.00
2019-05-13 2019-05-13 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
P - Purchase 15,000 205,590 7.87 9.88 148,200 2,031,229
2019-05-09 2019-05-07 4 AMRX Amneal Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -4,441 13,325 -25.00
2019-05-09 2019-05-07 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
F - Taxes -2,228 190,590 -1.16 13.44 -29,944 2,561,530
2019-05-09 2019-05-07 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
M - Exercise 4,441 192,818 2.36
2019-05-07 3 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
376,754
2019-05-07 3 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
376,754
2019-05-07 3 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
376,754
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)